Permira Is Said to Weigh €3 Billion-Plus Sale of Neuraxpharm
PositiveFinancial Markets

Permira is reportedly exploring the sale of Neuraxpharm, a pharmaceutical company specializing in central nervous system disorders, with a potential valuation between €3 billion and €4 billion. This move could significantly impact the market, reflecting the growing interest in companies that address critical health issues.
— Curated by the World Pulse Now AI Editorial System